Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
01 juil. 2024 05h10 HE
|
Alvotech
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech kynnir áætlaðar mettekjur og EBITDA framlegð á öðrum ársfjórðungi 2024
01 juil. 2024 05h10 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) kynnti í dag eftirfarandi óendurskoðaða áætlun um rekstrarniðurstöðu annars ársfjórðungs og á fyrri helmingi ársins 2024. Reiknað er með mettekjum Alvotech frá upphafi á...
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
26 juin 2024 04h50 HE
|
Alvotech
REYKJAVIK, Iceland , June 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Eigendur meirihluta breytilegra skuldabréfa Alvotech nýta rétt til að breyta yfir í hlutabréf
26 juin 2024 04h50 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að eigendur meirihluta breytilegra skuldabréfa félagins sem upphaflega voru útgefin 16. nóvember og 20. desember 2022 með lokagjalddaga 20. desember 2025, hafi...
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
26 juin 2024 04h50 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that holders of the majority of...
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
18 juin 2024 04h01 HE
|
Alvotech
Advanz Pharma secures rights to commercialize Alvotech’s biosimilar candidate for Eylea® in Europe Advanz Pharma will leverage its existing specialty and hospital capabilities in Europe to ensure...
Alvotech og Advanz Pharma undirrita samning um markaðssetningu í Evrópu á fyrirhugaðri líftæknilyfjahliðstæðu við Eylea
18 juin 2024 04h00 HE
|
Alvotech
Advanz Pharma fær rétt til markaðssetningar fyrirhugaðrar líftæknilyfjahliðstæðu við Eylea í Evrópu, en Alvotech þróar nú tvær útgáfur lyfsinsAdvanz Pharma mun nýta þekkingu á markaðssetningu...
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
18 juin 2024 04h00 HE
|
Alvotech
Advanz Pharma secures rights to commercialize Alvotech’s biosimilar candidate for Eylea® in EuropeAdvanz Pharma will leverage its existing specialty and hospital capabilities in Europe to ensure...
Alvotech and STADA add to strategic alliance through denosumab partnership
11 juin 2024 04h00 HE
|
Alvotech
STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central...
Alvotech and STADA add to Strategic Alliance through Denosumab Partnership
11 juin 2024 04h00 HE
|
Alvotech
STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central...